Review




Structured Review

Sequenom sequenom massarray platform
Box plots illustrating the DNA methylation of the miRNA genes investigated. The names of the miRNA <t>MassARRAY</t> amplicons analyzed by Sequenom are displayed at the top of each plot. The p-value (Wilcoxon test) for each amplicon analyzed is displayed on the second line at the top of the plot. The x-axis is divided into the two interval groups; early, representing Ella FFPE samples ≤ 5.2 years postpartum, and late, representing Ella FFPE samples ≥ 5.3 years postpartum. The y-axis represents the mean DNA methylation (%) of the amplicon.
Sequenom Massarray Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/sequenom+massarray/pmc04395255-133-12-11
Average 90 stars, based on 1 article reviews
sequenom massarray platform - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "Differentially Expressed MicroRNAs in Postpartum Breast Cancer in Hispanic Women"

Article Title: Differentially Expressed MicroRNAs in Postpartum Breast Cancer in Hispanic Women

Journal: PLoS ONE

doi: 10.1371/journal.pone.0124340

Box plots illustrating the DNA methylation of the miRNA genes investigated. The names of the miRNA MassARRAY amplicons analyzed by Sequenom are displayed at the top of each plot. The p-value (Wilcoxon test) for each amplicon analyzed is displayed on the second line at the top of the plot. The x-axis is divided into the two interval groups; early, representing Ella FFPE samples ≤ 5.2 years postpartum, and late, representing Ella FFPE samples ≥ 5.3 years postpartum. The y-axis represents the mean DNA methylation (%) of the amplicon.
Figure Legend Snippet: Box plots illustrating the DNA methylation of the miRNA genes investigated. The names of the miRNA MassARRAY amplicons analyzed by Sequenom are displayed at the top of each plot. The p-value (Wilcoxon test) for each amplicon analyzed is displayed on the second line at the top of the plot. The x-axis is divided into the two interval groups; early, representing Ella FFPE samples ≤ 5.2 years postpartum, and late, representing Ella FFPE samples ≥ 5.3 years postpartum. The y-axis represents the mean DNA methylation (%) of the amplicon.

Techniques Used: DNA Methylation Assay, Amplification

The x-axis shows the mean DNA methylation (%) of the miRNA Sequenom MassARRAY amplicons. The y-axis shows the miRNA expression levels as determined by quantitative RT-PCR analysis. The names of miRNA genes analyzed by MassARRAY and the names of the respective mature miRNA products detected by quantitative RT-PCR are displayed at the top of each plot. The Spearman correlation coefficient rho and the p-value (two-sided) of the correlation are displayed on the second line at the top of each plot.
Figure Legend Snippet: The x-axis shows the mean DNA methylation (%) of the miRNA Sequenom MassARRAY amplicons. The y-axis shows the miRNA expression levels as determined by quantitative RT-PCR analysis. The names of miRNA genes analyzed by MassARRAY and the names of the respective mature miRNA products detected by quantitative RT-PCR are displayed at the top of each plot. The Spearman correlation coefficient rho and the p-value (two-sided) of the correlation are displayed on the second line at the top of each plot.

Techniques Used: DNA Methylation Assay, Expressing, Quantitative RT-PCR

Related Articles

Mass Spectrometry:

Article Title: Genetic and Functional Dissection of the NFKB2 Gene: Implications for Milk Fatty Acid Biosynthesis in Dairy Cattle
Article Snippet: The PCR amplification products were bi‐directionally sequenced using an ABI3730XL DNA analyzer (Applied Biosystems, Foster, CA, USA) to identify potential polymorphisms. .. Subsequently, 1065 cows were genotyped on each identified SNP by using the matrix‐assisted laser‐desorption/ionization time of flight mass spectrometry (MALDI‐TOF MS, Sequenom MassARRAY, Bioyong Technologies Inc., HK). .. Using SAS 9.2, the phenotype–genotype association analyses between the identified SNP and 24 milk FA traits was conducted with the mixed animal model below, Y ijklm = μ + G i + h j + l k + a l + b × M m + e ijklm In which, Y ijklm was the phenotypic value of each milk FA trait; μ was the overall mean; G i was the fixed effect corresponding to the genotype combination of individual i ; h j ( j = 1–23) and l k ( k = 1–4) were the fixed effect of farm j and stage of lactation l , respectively; a l was the random polygenic effect; M m ( m = 1–293) was the fixed effect of age at calving m ; b was the regression coefficient of covariate M ; and e ijklm was the random residual.

Article Title: FCRL3 genetic variants drive autoimmune pathogenesis in multiple sclerosis and neuromyelitis optica spectrum disorders
Article Snippet: .. This was carried out using the matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) platform (MassArray TM, Sequenom Inc., San Diego, CA, USA), following a previously established method ( ). .. PCR and extension primers were designed using MassArray Assay Design 3.1 software (Sequenom, San Diego, CA, USA) ( ).

Genotyping:

Article Title: FCRL3 genetic variants drive autoimmune pathogenesis in multiple sclerosis and neuromyelitis optica spectrum disorders
Article Snippet: Genomic DNA extraction from peripheral blood mononuclear cells was conducted using the QIAamp DNA Blood Minikit (QIAGEN, Hilden, Germany) according to the manufacturer’s instruction. .. All participants underwent genotyping utilizing the Sequenom MassArray system. ..

Matrix-assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry:

Article Title: FCRL3 genetic variants drive autoimmune pathogenesis in multiple sclerosis and neuromyelitis optica spectrum disorders
Article Snippet: .. This was carried out using the matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) platform (MassArray TM, Sequenom Inc., San Diego, CA, USA), following a previously established method ( ). .. PCR and extension primers were designed using MassArray Assay Design 3.1 software (Sequenom, San Diego, CA, USA) ( ).

Mutagenesis:

Article Title:
Article Snippet: .. RAS/RAF mutation status of the ascites and matching tumor biopsies were determined by Sanger sequencing (ascites) and Sequenom analysis (tumor). ..

Sequencing:

Article Title:
Article Snippet: .. RAS/RAF mutation status of the ascites and matching tumor biopsies were determined by Sanger sequencing (ascites) and Sequenom analysis (tumor). ..

Polymerase Chain Reaction:

Article Title: Method for treatment of hypertension
Article Snippet: .. Each sample will be analyzed using 2 different methodologies, the Sequenom MassArray genotyping platform and classical PCR and gel sizing to determine insertion/deletion status. .. The Sequenom MassArray genotyping platform will be used to analyze the following sites-rs1042713, rs1042714, rs1801252, rs1801253, rs4961, rs2228576, rs1529927, rs1159744, rs2107614, rs2277869, rs12750834, rs5051, rs699, rs7079 and rs5186.

Multiplex Assay:

Article Title: Evidence of Genetic Isolation and Differentiation Among Historically Fragmented British Populations of Common Juniper, Juniperus communis L.
Article Snippet: .. Of these 175 loci, 80 were selected for two multiplex Sequenom assays (Bradić et al. ), which ultimately provided data at 74 SNP loci for all samples (Table ). ..

other:

Article Title: Compositions and methods for treating cancer
Article Snippet: Detection of one or more mutations may also utilize an array of probes (also referred to as a “DNA chip” assay, e.g. a GeneChip assay-Affymetrix, Santa Clara, CA).



Similar Products

96
agena bioscience agena massarray methylation detection
Agena Massarray Methylation Detection, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/Methylation/ppr0552502-125-0-0
Average 96 stars, based on 1 article reviews
agena massarray methylation detection - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

90
Sequenom massarray methylation detection
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Methylation Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/massarray+quantitative+methylation+analysis/pmc09085879-231-0-4
Average 90 stars, based on 1 article reviews
massarray methylation detection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

96
agena bioscience massarray system methylation detection amplification pcr reaction
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/Methylation/pm31002356-111-8-15
Average 96 stars, based on 1 article reviews
massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
agena bioscience agena massarray system methylation detection amplification pcr reaction
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Agena Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/Methylation/pm31002356-111-7-15
Average 96 stars, based on 1 article reviews
agena massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Journal: Cell Death & Disease

Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

doi: 10.1038/s41419-022-04895-6

Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Article Snippet: MassARRAY methylation detection technology (Sequenom, USA) performed by CapitalBio Technology (Shanghai, China) was used to detect the methylation level of ZNF334 promoter (human) in carcinoma and paracancerous tissues of 25 HCC patients and Zfp334 promoter (mice) in treatment and control group.

Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing